Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ANO1 | Q5XXA6 | 6/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.46 |
| ▸ | RORA | P35398 | 1/20 | 0.46 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.46 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.45 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22734270 | 0.83 | TSHR (0.58) | ALDH1A1 | |
| SCHEMBL22734285 | 0.78 | ANO1 (0.54) | ANO1ALDH1A1 | |
| SCHEMBL28600470 | 0.73 | KMT2A (0.66) | KCNQ2KCNJ5KCNJ3ALDH1A1 | |
| SCHEMBL21198480 | 0.72 | ANO1 (0.71) | ANO1KCNJ5KCNJ3KCNJ6 | |
| SCHEMBL31306626 | 0.72 | ANO1 (0.71) | ANO1KCNJ5KCNJ3KCNJ6 | |
| SCHEMBL28000208 | 0.72 | GALR3 (0.60) | NPC1RAB9AP2RX7THRBALDH1A1 | |
| SCHEMBL1307479 | 0.71 | MEN1 (0.54) | NPC1RAB9AANO1KCNJ5KCNJ3 | |
| SCHEMBL7724422 | 0.70 | MAPT (0.62) | NPC1RAB9AKCNQ2KCNJ5KCNJ3 | |
| SCHEMBL2184203 | 0.69 | RORA (0.71) | NPC1RAB9AANO1RORANR2E1 | |
| SCHEMBL30502369 | 0.69 | KCNJ5 (0.68) | NPC1RAB9AANO1KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200383988-A1 | Compounds | ENTERPRISE THERAPEUTICS HOLDINGS LIMITED (GB) | 2020-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383988-A1 | Compounds | CACNA1E, TMEM109, CACNA1A | NPC1 324/4885RAB9A 343/4885ANO1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.